Untargeted metabolomics combined with CYP2C19 gene polymorphism data yielded eight compounds associated with CYP2C19 phenotype, and further studies are needed to evaluate the usefulness of these compounds as biomarkers of CYP2C19 activity.
Abstract
Background/Objectives: Cytochrome P450(CYP)2C19 activity varies widely among individuals. As genetic factors, CYP2C19*2 and CYP2C19*3 alleles reduce CYP2C19 activity, while the CYP2C19*17 allele increases CYP2C19 activity. However, environmental and physiological factors can also influence individual CYP2C19 activity. In this study, we searched for novel endogenous biomarkers for CYP2C19 activity using CYP2C19 gene polymorphism data combined with results of untargeted metabolomic analysis. Methods: 431 general adults analyzed in the Kyoto J-MICC Study and 255 patients who visited Oita University Hospital were studied. Plasma samples were pretreated by solid-phase and liquid-liquid extraction and subjected to untargeted metabolomic analysis using ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. Based on CYP2C19 gene polymorphism data, participants were classified into extensive metabolizers (EM), intermediate metabolizers (IM), and poor metabolizers (PM). Compounds showing significant differences in abundance among the three groups were considered candidate compounds for predicting CYP2C19 activity. The predictive performance of candidate compounds for CYP2C19 PM status was evaluated using covariate-adjusted receiver operating characteristic (ROC) analysis. Results: The normalized abundance of compounds with m/z 160.1342, 303.2319 (a fatty acyl or prenol lipid), 314.2309, 449.3238, 653.3021, 792.5744, and 811.5988 (a glycerophospholipid or sphingolipid), and 902.5404 (a fatty acyl) differed significantly among CYP2C19 EM, IM, and PM groups (p < 0.05), and these eight compounds were considered candidate compounds. Covariate-adjusted ROC analysis showed that none of the candidate compounds significantly improved the discrimination of CYP2C19 PM status. Conclusions: Untargeted metabolomics combined with CYP2C19 gene polymorphism data yielded eight compounds associated with CYP2C19 phenotype. Further studies are needed to evaluate the usefulness of these compounds as biomarkers of CYP2C19 activity.
Background Cytochrome P450 3A5 (CYP3A5) is a key xenobiotic‐metabolizing enzyme that also participates in the biotransformation of endogenous substrates. Functional genetic variation within CYP3A5 can alter enzyme activity and may consequently modify individual susceptibility to malignancy. The contribution of CYP3A5 g...
Reliable endogenous biomarkers for assessing CYP3A activity and clinical drug-drug interaction (DDI) risk remain limited. We characterized global metabolomic changes following itraconazole treatment in a fixed-sequence DDI study (11 healthy volunteers) to identify novel CYP3A endogenous biomarkers. Untargeted metabolom...
S. Yee, Eugene P. Kadar, Matthew A. Cerny et al.· Clinical pharmacology and th...· 0 citations
The distribution of CYP2C19 polymorphisms and associated metabolizer phenotypes varies across populations. There is a lack of large scale pooled data on CYP2C19 polymorphisms and associated metabolizer phenotypes in Indian population. This systematic review and meta analysis aimed to determine the prevalence of CYP2C19...
Smriti Singh, Chanchal Goyal, Tejas K. Patel et al.· Indian Journal of Pharmacolo...· 0 citations
Sertraline, a commonly used first-line antidepressant for major depressive disorder, is primarily metabolized by the polymorphic cytochrome P450 enzymes CYP2C19 and CYP2B6. This large-scale Chinese cohort study (N = 1070 patients; 1414 serum concentration measurements) evaluated whether incorporating CYP2B6 phenotype p...
Yu-Hang Yan, Yue-Yao Luan, Qi-Xuan Sun et al.· Progress in Neuro-psychophar...· 0 citations
Numerous pharmacogenomic (PGx) associations of pharmacokinetics and pharmacodynamics of commonly prescribed medications have been reported. Yet, the evidence supporting their association on survival remains underexamined. We sought to investigate the CYP2D6‐metoprolol association and determine whether the established v...
S. de Denus, Essaïd Oussaïd, Maxime Meloche et al.· Clinical and Translational S...· 0 citations
Given that functional annotations for CYP2D6 alleles are well established, WGS-based comprehensive detection represents a practical and scalable strategy for pharmacogenomic profiling and is expected to support optimized drug selection and advance personalized medicine.
Sumiko Ohnami, Takeshi Nagashima, K. Hatakeyama et al.· Journal of Toxicological Sci...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.